Submitted by Anonymous (not verified) on 21 August 2026 - 13:19
Orphan designation: Eculizumab Treatment of Guillain-Barré syndrome, 11/10/2022 Withdrawn
Source:
Orphan designation: Eculizumab Treatment of Guillain-Barré syndrome, 11/10/2022 Withdrawn